NCT04167631
Can VI-RADS/ADC Accurately Stage Bladder Cancer??
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Notable Primary completion date: Dec 1, 2023 to Dec 1, 2024
- Study completion date: Jan 1, 2024 to Dec 2024
- Notable Primary completion date: Jun 1, 2020 to Dec 1, 2023
- Study completion date: Jun 1, 2020 to Jan 1, 2024
- Minor Study title shortened, about 3 wordsv3
- Minor Study description expanded, about 75 words
- Study title shortened, about 10 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Vesical Imaging-Reporting And Data System (VI-RADS) for discriminating muscle invasive bladder cancer (MIBC) from non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
Timeframe: 18 months
Arms and interventions
Multiparametric MRIOther
Vesical Imaging-Reporting And Data System (VI-RADS) using multi-parametric MRI.
Radiation: Multi-parametric MRI
Sites
1 site in 1 country
- Urology and Nephrology CenterAl Mansurah, Aldakahlia, Egypt